$0.15
0.00 (-0.54%)
Open$0.16
Previous Close$0.15
Day High$0.16
Day Low$0.14
52W High$2.88
52W Low$0.15
Volume—
Avg Volume17.40M
Market Cap4.98M
P/E Ratio—
EPS$-1.76
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,116.1% upside
Current
$0.15
$0.15
Target
$3.24
$3.24
$1.82
$3.24 avg
$4.40
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 31.1K | 180.6K | 15.18M |
| Net Income | -85,107,885 | -444,041,139 | 1.21M |
| Profit Margin | -279,263.6% | -265,300.5% | 8.0% |
| EBITDA | -91,489,575 | -503,855,630 | 1.98M |
| Free Cash Flow | — | — | 1.07M |
| Rev Growth | -82.8% | -82.8% | +1.7% |
| Debt/Equity | — | — | 0.33 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |